Drugs for epilepsy in adolescent girls

Comparison of efficacy and tolerability of levetiracetam and valproate for newly diagnosed generalised and unclassifiable epilepsy in adolescent girls aged 10-18 years: a randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075501

Enrollment

302

Registered

2024-10-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G403- Generalized idiopathic epilepsy and epileptic syndromes

Interventions

Intervention1: Valproate: Valproate tablet (500 mg) orally twice daily for 24 weeks Control Intervention1: Levetiracetam: Levetiracetam tablet (500 mg) orally twice daily for 24 weeks

Eligibility

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed case of generalized or unclassifiable epilepsy 2.History of at least one convulsive seizure within previous one month

Exclusion criteria

Exclusion criteria: 1. Parents not providing informed consent 2. Adolescent suffering fromc hronic hepatic or renal disease 3. Only acute symptomatic seizures

Design outcomes

Primary

Measure	Time frame
Number of participants with seizure freedomTimepoint: At 24 weeks	—

Secondary

Measure	Time frame
Number of participants with any adverse effect due to study medicationTimepoint: 24 weeks	—

Countries

India

Contacts

Public ContactDr Prateek Kumar Panda

AIIMS, RISHIKESH

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026